Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.68 |
| ▸ | PPARG | P37231 | 4/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441283 | 1.00 | PPARA (0.68) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL199415 | 1.00 | PPARA (0.68) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL4797933 | 0.94 | PPARG (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL4094724 | 0.94 | PPARG (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL8976947 | 0.93 | PPARA (0.60) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3821796 | 0.92 | PPARA (0.60) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL20187250 | 0.90 | CTSS (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3840582 | 0.90 | PPARG (0.58) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL18228983 | 0.90 | CTSS (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL10034081 | 0.90 | PPARG (0.60) | PPARAPPARGACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | claimed |
| CN-114539158-A | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2022-05-27 | — | — | CN | claimed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4538258-A1 | IMIDAZOLIDINYL VANILLIC ACID ETHER DERIVATIVE AND USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-20250049937-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4453000-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-117480164-B | Factor XIa inhibitor and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-1988001618-A1 | BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE | GANSOW OTTO A (US) | 1988-03-10 | — | — | WO | disclosed |
| EP-0220279-A1 | METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE | GANSOW, Otto A. (US) | 1987-05-06 | — | — | EP | disclosed |
| EP-0217286-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1987-04-08 | — | — | EP | disclosed |
| WO-1986006384-A1 | METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE | GANSOW OTTO A (US) | 1986-11-06 | — | — | WO | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049937-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | AURKC, AURKA, AURKB | PPARA 3815/4885PPARG 3158/4885ACE 3756/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | PPARA 1801/4885PPARG 2449/4885ACE 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.